NUCYNTA® (tapentadol), designed as a novel short‑acting opioid, offers the same active molecule as NUCYNTA® ER (tapentadol) extended‑release tablets, CII
The use of any opioid may result in serious, life‑threatening, or fatal respiratory depression, even when used as recommended.
See phase 3 data demonstrating the strength of NUCYNTA
for patients with moderate to severe acute pain.
Learn about our co‑pay savings offer for your commercially‑insured patients.